1987/01/01 by J.P. Pointel, J P Pointel, H. Boccalon +5
Medicine · #Botulinum Toxin and Related Neurological Disorders #Peripheral Nerve Disorders #Stroke Rehabilitation and Recovery
paper · doi:10.1177/000331978703800106
crossref issued 1987/01/01 · crossref published 1987/01/01 · crossref published-online 1987/01/01 · crossref published-print 1987/01/01 · openalex publication_date 1987/01/01 · crossref created 2007/11/26 · openalex created_date 2025/10/10 · crossref deposited 2026/04/28 · crossref indexed 2026/07/30 · openalex updated_date 2026/07/31
Ninety-four patients suffering from venous insufficiency of the lower limbs participated in a multicenter, double-blind versus placebo study. After randomization, they were allotted for a treatment period of two months to one of three groups: TECA 120 mg/day, TECA 60 mg/day, or placebo. A significant difference (p less than 0.05) in favor of TECA was shown for the symptoms of heaviness in the lower limbs and edema, as well as for the overall evaluation by the patient. The venous distensibility measured by a mercury strain gauge plethysmograph at three occlusion pressures was improved for the TECA groups but aggravated for the placebo group.